Shukaib Arslan1, Ryotaro Nakamura2. 1. Department of Hematology & Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, 91010, USA. 2. Department of Hematology & Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, 91010, USA. rnakamura@coh.org.
Abstract
PURPOSE OF REVIEW: Myelodysplastic syndrome (MDS) is a heterogeneous hematological disorder characterized by a spectrum of clinical presentation, cytogenetic, and somatic gene mutations and the risk of transformation to acute leukemia. Management options include observation, supportive care, blood transfusion, administration of growth factors and/or hypomethylating agents, and hematopoietic cell transplant (HCT) either upfront or after disease progression. RECENT FINDINGS: Currently, HCT is the only curative therapy available for patients with MDS, with multiple factors such as donor availability, patient, and disease characteristics being involved in making the decision to proceed with transplant. In this article, we summarize (1) overall prognosis and natural history of MDS, (2) currently available non-HCT therapy with a focus on hypomethylating agents (HMA), (3) outcomes after HCT in patients with MDS, (4) factors to be considered to proceed to HCT for treatment of MDS, and (5) more recent/ongoing studies relevant to HCT decision-making processes.
PURPOSE OF REVIEW: Myelodysplastic syndrome (MDS) is a heterogeneous hematological disorder characterized by a spectrum of clinical presentation, cytogenetic, and somatic gene mutations and the risk of transformation to acute leukemia. Management options include observation, supportive care, blood transfusion, administration of growth factors and/or hypomethylating agents, and hematopoietic cell transplant (HCT) either upfront or after disease progression. RECENT FINDINGS: Currently, HCT is the only curative therapy available for patients with MDS, with multiple factors such as donor availability, patient, and disease characteristics being involved in making the decision to proceed with transplant. In this article, we summarize (1) overall prognosis and natural history of MDS, (2) currently available non-HCT therapy with a focus on hypomethylating agents (HMA), (3) outcomes after HCT in patients with MDS, (4) factors to be considered to proceed to HCT for treatment of MDS, and (5) more recent/ongoing studies relevant to HCT decision-making processes.
Entities:
Keywords:
Allogeneic hematopoietic cell transplant (HCT); Hypomethylating agents (HMA); International Prognostic Scoring System (IPSS); Myelodysplastic syndrome (MDS); Revised International Prognostic Scoring System (IPSS-R)
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: J M Hows; J R Passweg; A Tichelli; A Locasciulli; R Szydlo; A Bacigalupo; N Jacobson; P Ljungman; J Cornish; A Nunn; B Bradley; G Socié Journal: Bone Marrow Transplant Date: 2006-10-30 Impact factor: 5.483
Authors: Lori Muffly; Marcelo C Pasquini; Michael Martens; Ruta Brazauskas; Xiaochun Zhu; Kehinde Adekola; Mahmoud Aljurf; Karen K Ballen; Ashish Bajel; Frederic Baron; Minoo Battiwalla; Amer Beitinjaneh; Jean-Yves Cahn; Mathew Carabasi; Yi-Bin Chen; Saurabh Chhabra; Stefan Ciurea; Edward Copelan; Anita D'Souza; John Edwards; James Foran; Cesar O Freytes; Henry C Fung; Robert Peter Gale; Sergio Giralt; Shahrukh K Hashmi; Gerhard C Hildebrandt; Vincent Ho; Ann Jakubowski; Hillard Lazarus; Marlise R Luskin; Rodrigo Martino; Richard Maziarz; Philip McCarthy; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Attaphol Pawarode; Edward Peres; Andrew R Rezvani; David Rizzieri; Bipin N Savani; Harry C Schouten; Mitchell Sabloff; Matthew Seftel; Sachiko Seo; Mohamed L Sorror; Jeff Szer; Baldeep M Wirk; William A Wood; Andrew Artz Journal: Blood Date: 2017-07-03 Impact factor: 22.113
Authors: Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai Journal: Blood Date: 2018-10-25 Impact factor: 22.113
Authors: A Nazha; M Narkhede; T Radivoyevitch; D J Seastone; B J Patel; A T Gerds; S Mukherjee; M Kalaycio; A Advani; B Przychodzen; H E Carraway; J P Maciejewski; M A Sekeres Journal: Leukemia Date: 2016-05-20 Impact factor: 11.528
Authors: Katarzyna Duda; Agata Wieczorkiewicz-Kabut; Adrianna Spałek; Anna Koclęga; Anna J Kopińska; Krzysztof Woźniczka; Grzegorz Helbig Journal: Indian J Hematol Blood Transfus Date: 2021-12-10 Impact factor: 0.915